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Abstract Biomarkers are considered as tools to enhance
cardiovascular risk estimation. However, the value of
biomarkers on risk estimation beyond European risk
scores, their comparative impact among different European
regions and their role towards personalised medicine
remains uncertain. Biomarker for Cardiovascular Risk
Assessment in Europe (BiomarCaRE) is an European col-
laborative research project with the primary objective to
assess the value of established and emerging biomarkers
for cardiovascular risk prediction. BiomarCaRE integrates
clinical and epidemiological biomarker research and
commercial enterprises throughout Europe to combine
innovation in biomarker discovery for cardiovascular dis-
ease prediction with consecutive validation of biomarker
effectiveness in large, well-deﬁned primary and secondary
prevention cohorts including over 300,000 participants
from 13 European countries. Results from this study will
contribute to improved cardiovascular risk prediction
across different European populations. The present publi-
cation describes the rationale and design of the Biomar-
CaRE project.
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Despite signiﬁcant advances in treatment, cardiovascular
disease (CVD) remains the leading cause of death world-
wide. Traditional risk factors including dyslipidemia,
hypertension, diabetes, obesity, and smoking account for a
large proportion of the risk of myocardial infarction and
stroke globally [36]. Most of these traditional risk factors
are modiﬁable and their management is likely to reduce
risk of CVD in both primary and secondary prevention
settings [12]. However, risk estimates based on these
classical risk factors only partially explain CVD incidence
in the general population and risk estimates vary across
European populations. Despite the availability of various
global risk assessment scores like the Framingham Score
[7], the PROCAM Score [3] and the European Society of
Cardiology SCORE [6], prediction of cardiovascular
events is incomplete and a considerable number of patients
at risk go unidentiﬁed on the basis of traditional risk factors
alone. Khot et al. [18] have reported that 62 % of patients
with MI present with none or only one risk factor and less
than 10 % show three or four risk factors. To improve risk
estimation above and beyond traditional risk scores, and to
improve therapy decision making and guidance, novel
(emerging) biomarkers are of considerable interest [4]. A
number of those biomarkers are thought to provide addi-
tional prognostic information; however, only few studies
have evaluated a large panel of biomarkers [4]. Therefore,
it is not clear whether these proposed biomarkers might
merely be proxies for known risk factors and therefore
whether they really provide incremental predictive and
discriminatory information. Most importantly, are there so
far undetected novel biomarkers that might perform even
better than known biomarkers?
Molecular omics-based approaches such as proﬁling of
microRNAs, the proteome of microparticles, the tran-
scriptome and the metabolome represent new and promis-
ing approaches for the discovery of novel biomarkers and
might lead to the identiﬁcation of markers which better
distinguish individuals who may experience incident car-
diovascular events. Overall, risk estimation needs to be
assessed across populations in different European regions,
as well as in the secondary prevention setting where even
less is known about the performance of established and
novel biomarkers for risk estimation. Ultimately, we need
to know whether a modiﬁed risk estimation model will
translate into a change in treatment [4].
Within the BiomarCaRE project, promising novel bio-
markers will be selected in order to develop risk estimation
models for incident CVD and they will be validated across
European populations. Success in building a robust pre-
diction score could greatly facilitate individualized risk
estimation, screening, and diagnosis of CVD. The novel
risk score would have the potential to change existing
clinical guidelines and could thus have signiﬁcant public
health impact.
The consortium
The collaborative BiomarCaRE consortium, an FP7 funded
project, integrates the efforts of 25 academic institutions
and ﬁve small/medium-sized, research intensive enterprises
(SMEs) with a focus on cardiovascular biomarker research
across Europe (Fig. 1). BiomarCaRE brings together large-
scale epidemiological and clinical data and biomaterial
resources across Europe and diverse expertise in epidemi-
ology, clinical research, data and sample management,
clinical chemistry, molecular biology, and biostatistics.
The consortium capitalizes on in depth knowledge of
omics-based candidate markers and integrates modern
technologies of multiple biomarker assessment. It com-
prises 21 well-established prospective European popula-
tion-based cohort studies, most of which were previously
harmonized in the MORGAM Project [9], four cohorts of
diseased subjects (disease cohorts, secondary prevention)
and four clinical trials, totalling over 300,000 participants
with a follow-up of over three million person years and
storage of selected biomaterial of all participants in one
central BiomaCaRE laboratory (University Heart Center
Hamburg). This large individual-based database provides a
unique opportunity to investigate the performance of
established and novel biomarkers for Cardiovascular Risk
Assessment across Europe.
An academic partner coordinates the consortium; the
focus, however, is constructed around novel, emerging
biomarkers and innovative technology and assays derived
by SMEs. The consortium comprises an established
research governance infrastructure, data harmonization and
sharing arrangements, two central secure, access-managed
phenotypic and biomarker data repositories as well as a
core laboratory for biomarker measurements.
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123Objective of BiomarCaRE
The objective of the BiomarCaRE consortium is to com-
bine innovation in biomarker discovery with validation of
newly identiﬁed and established biomarkers for CVD
prediction across Europe. Ultimately, the BiomarCaRE
consortium aims to develop a ‘‘European biomarker panel’’
for CVD prediction including classical risk factors and
established and novel biomarkers. This will be achieved on
the basis of SME-driven development of innovative tech-
nology and immunological/clinical chemistry assays and a
large collaboration of well-deﬁned European cohorts in
primary and secondary prevention. The BiomarCaRE
consortium measures success not only in terms of devel-
opment of novel risk estimation models and their sub-
sequent clinical utility, but also in terms of the
development of novel, innovative technologies.
Methods
Design of BiomarCaRE
The BiomarCaRE project is designed as a multi-modular
study including: (1) biomarker selection based on omics
discovery studies as well as literature, and (2) assay
development (Module 1), (3) data harmonization of large-
scale studies and (4) biomarker determination, analyses and
validation (Module 2), and (5) biomarker assessment in
clinical trials and (6) economic evaluation (Module 3). The
main disease endpoints assessed in BiomarCaRE are inci-
dent acute coronary events, stroke, heart failure, atrial
ﬁbrillation, and diabetes mellitus. Other cardiovascular
endpoints such as venous thrombosis will also be studied.
Figure 2 gives a detailed overview about the multi-modular
BiomarCaRE design.
Fig. 1 BiomarCaRE collaborating countries and cohorts across Europe. Asterisk indicates cohort with imaging data available
The BiomarCaRE study 779
123Cohorts, variables and biomaterial in BiomarCaRE
An overview of all cohorts, follow-up times and available
biomaterial samples is outlined in Tables 1, 2, 3, 4, 5, 6 and
a detailed description of the cohorts is provided in the
Supplementary Material. For each cohort, ethical approval
has been granted by the respective Ethical Committees and
each participant gave informed consent.
Population-based cohorts
The population cohorts originate from different countries
of all European regions (Fig. 1). Each cohort is based on a
well-deﬁned population. Consistent measurement and data
collection procedures were used for demographic, lifestyle,
biological and clinical data. Some of the cohorts have
ultrasound-based imaging and magnetic resonance imaging
(MRI) data available (Table 1). Overall, the general pop-
ulation cohorts comprise 171,000 men and 129,000
women; 45,000 of them have serially sampled biomarkers
available. The mean age at baseline is 51.2 (SD 12.7) years.
All cohorts include subjects in mid-life, a time when early
onset CVD manifests and where it is of importance to
target improved risk estimation (Table 2). All cohorts
followed-up the study participants prospectively for a
range of 2.5–25 years for fatal and non-fatal acute coronary
events and stroke and death. Some of the cohorts also
followed-up heart failure, atrial ﬁbrillation, type 2 diabetes,
peripheral vascular disease, venous thromboembolism, and
cancer.
The harmonised baseline variables include measured
systolic and diastolic blood pressure, blood lipids, weight,
height, waist and hip circumference, and questions on
smoking, disease history and medication for hypertension,
dyslipidaemia and diabetes. Assessment and validation of
the end-points varied between cohorts (Kulathinal et al.
[20] ). Acute coronary events are harmonized to categories:
deﬁnite or possible myocardial infarction or coronary
death, unstable angina pectoris, cardiac revascularization,
or unclassiﬁable death, where the data are insufﬁcient for
the other coronary diagnoses and there is no evidence of
other causes. The categories can be combined to deﬁne
different end-points for analysis. Stroke has been charac-
terized as ischaemic stroke, intracerebral haemorrhage, and
subarachnoid haemorrhage, although reliable diagnostic
information for the subtyping is not always available, in
Fig. 2 BiomarCaRE multi-modular concept. From biomarker selec-
tion and assay development (Module 1) to biomarker measurements
and statistical analyses (Module 2) to clinical translation and
economic assessment (Module 3). Module 1: Established and
emerging biomarkers are prioritised according to their association
with CVD risk, novel biomarkers are selected based on pre-existing
non-publically available-omics datasets. Assay development is guided
by SMEs and optimised for medium to high-throughput measurement.
Module 2: The predictive value of biomarkers is assessed separately
in population and disease based cohorts in a two phase approach;
phase I assessment and phase II validation. Module 3 assesses the
clinical utilisation of BiomarCaRE risk panels in clinical trials for
their interaction with risk lowering therapy and develops a decision-
analytical model to estimate long term cost-effectiveness of a primary
or secondary preventive strategy guided by biomarker testing
780 T. Zeller et al.
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123particular for the early years of follow-up. Follow-up for
heart failure, atrial ﬁbrillation, type 2 diabetes, peripheral
vascular disease, venous thromboembolism and cancer
were usually based on linkage with national hospitalization
registers, other administrative registers and cancer
registers.
Disease cohorts
In patients with manifest CVD, in particular after an acute
coronary syndrome (ACS), a number of clinical variables
have been proven useful for risk assessment. These vari-
ables have been integrated into various scores like the
Thrombolysis in Myocardial Infarction (TIMI) Risk Score,
and the Global Registry of Acute Coronary Event
(GRACE) Score. Based on such parameters fairly reliable
prediction can be made not only short-term but even over a
period of more than 5 years [11]. However, despite such
routinely available variables, further improvement of risk
assessment in this high-risk group is of paramount impor-
tance because available treatment options should be tai-
lored to the individual patient’s risk. The BiomarCaRE
consortium offers the opportunity to directly translate
population-derived biomarker information into the clinical
setting of manifest CVD and ACS. Within the consortium
four disease cohorts comprising almost 9,000 individuals
with either angiographically proven stable coronary artery
disease (CAD) mostly after myocardial infarction or indi-
viduals presenting with suspected acute ACS have been
harmonized for CVD history, clinical symptoms and clas-
sical cardiovascular risk factor information. The clinical
endpoints followed up in the disease cohorts are (1) total
mortality, (2) cardiac death, (3) cardiovascular death
including fatal cardiovascular events such as cerebrovas-
cular diseases, and (4) cardiovascular events including the
combined endpoint of cardiovascular death and non-fatal
myocardial infarction (Table 3). The mean age is 61.5 (SD
12.4) years. Follow-up varies between 6 months and
7.5–10 years. Baseline variables are outlined in Table 4.
Combining data from different diseases cohorts in Bio-
marCaRE, in particular from the AtheroGene and KARO-
LA studies with long-term follow-up, guarantees sufﬁcient
power to reliably describe biomarker associations with
recurrent cardiovascular events and to test the applicability
of a marker panel in diverse clinical settings.
Clinical trials
Various biomarkers may be affected by contemporary
pharmacological strategies as seen for example in the case
of hsCRP and statin treatment [24]. This biomarker may be
lowered by 40 % when highly potent statins are given.
Thus, it may be important to test the effects of various
therapies on our ﬁnally selected biomarkers. Based on
access to biobanks of several large clinical trials, Bio-
marCaRE will test biomarkers as measures of therapeutic
response related to aspirin in women (Women ´s Health
Study), LDL-Cholesterol lowering by statins (The Long-
Term Intervention with Pravastatin in Ischaemic Disease
(LIPID) Study and The Justiﬁcation for the Use of Statins
in Primary Prevention: An Intervention Trial Evaluating
Rosuvastatin (JUPITER) trial), and anti-inﬂammatory
treatment with an Lp-PLA2 inhibitor (darapladib) [Inte-
grated Biomarker and Imaging Study-2 (IBIS-2)]
(Table 5).
Biomaterial
A prerequisite for all BiomarCaRE cohorts is the avail-
ability of biomaterial samples, such as plasma, serum and
genomic DNA. Furthermore, innovative biomaterial such
as plaque tissue is also available in some of the Biomar-
CaRE cohorts. The Cohort Centres select samples from
their repositories and transfer them to the BiomarCaRE
central laboratory in Hamburg, Germany, where the mea-
surement of all established and novel biomarkers is
performed.
Selected established, emerging, and ‘‘omics-based’’
biomarkers, and assay development by SMEs
In Module 1 of the project (Fig. 2), established biomarkers
are selected according to their association with the risk of
CVD, and based on the expertise and knowledge of the
BiomarCaRE consortium and the public domain. The Bi-
omarCaRE consortium has already determined an exten-
sive panel of biomarkers within the MORGAM Biomarker
substudy [4]. Key established biomarkers to be addressed
are high-sensitivity troponins (hsTn), natriuretic peptides,
high-sensitivity C-reactive protein (CRP), lipids, and fur-
ther markers of cardiomyocyte micronecrosis, inﬂamma-
tion, and renal function (Fig. 3). The concept of biomarkers
reﬂecting different underlying pathways to disease pro-
gression combined in multiple biomarker risk scores has
already been applied in several population-based studies [4,
14, 21, 25, 39] as well as in disease cohorts [26]. Several of
those markers, in particular hsTn, hsCRP as well as growth
differentiation factor 15 (GDF-15) have been proposed to
guide therapy [1, 17, 24]. Commercially available assays
are used to determine the levels of established biomarkers
in the biomaterial of study participants.
Selection of novel biomarkers is based on pre-existing
but not publicly available –omics datasets on quantitative
proteomics, transcriptomics, metabolomics, and miR-
Nomics. The emerging value of circulating microRNAs
(miRNAs) and circulating cells such as microparticles as
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123speciﬁc and sensitive biomarkers has been discussed by
several groups [10, 16, 33, 34]. In addition, assessment of
the transcriptome can identify disease-related mRNA sig-
natures which might be translated into clinically useful
biomarkers [22, 31, 37]. Apart from proteomics and
transcriptomics approaches, metabolite proﬁling in large,
well-phenotyped cohorts is very rapidly emerging in the
cardiovascular ﬁeld [23, 27, 28, 35] and provides access to
a biomolecular repertoire not covered by other omics
applications.
The novel biomarkers are disclosed by the academic and
SME partners. The SMEs introduce the technology and
guide the development of the innovative assays needed for
the measurement of novel biomarkers. In addition, the
SMEs optimise the required technology so that medium- to
high-throughput measurements become possible. Assay
validation has been carried out before incorporation by the
BiomarCaRE laboratory. The following technologies are
established to apply omics-based discovery results in
population based and disease cohorts: a) A microparticle-
Table 2 Overall characteristics of the BiomarCaRE population
cohorts
Characteristics
Number of cohort studies
a 21
Number of individuals 300,000
Years of baseline examinations 1982–2012
Men (%) 57 %
Mean age (SD) at baseline (years) 51.2 (12.7)
Smoker (%) 38 %
Diabetes (%) 5 %
Hypertension (%)
b 42 %
Number of incident endpoints during follow-up
Acute coronary events
c 13,700
Stroke
d 8,400
Heart failure
e 3,800
Atrial ﬁbrillation
f 2,900
Type 2 diabetes
g 3,400
Overall Death
h 35,600
Number are given for distinct individuals, excluding repeated
measurements
a Status as of June 2014
b Blood pressure[140/90 or under treatment
c Deﬁnite or possible myocardial infarction or coronary death, or
unstable angina pectoris. The number is available for 33 cohorts,
estimated for 2 cohorts. Excluding individuals with history of car-
diovascular disease
d The number is available for 34 cohorts, estimated for 1 cohort.
Excluding individuals with history of cardiovascular disease
e The number is available for 11 cohorts, estimated for 1 cohort.
Excluding individuals with history of heart failure
f The number is available for 10 cohorts. Excluding individuals with
history of atrial ﬁbrillation
g The number is available for 13 cohorts, estimated for 1 cohort.
Excluding individuals with history of type 1 or type 2 diabetes
h The number is available for 37 cohorts, given for 1 cohort
Table 3 Disease cohorts of BiomarCaRE
Study Country Size Follow-up time
(years)
Endpoints Biomaterial
Total
mortality
Cardiac
death
Cardiovascular
death
Cardiovascular
events
Serum EDTA
Plasma
DNA
AtheroGene Germany 3,476 7.5 386 244 260 460 •• •
KAROLA Germany 1,204 10 184 91 103 162 •• •
APACE Switzerland 2,248 2.2 174 71 73 534 •• –
stenoCardia Germany 1,818 0.5 34 0 7 38 •• •
Rome
ACB*
Italy 500
a –– – – •• –
The disease cohorts of the project are listed including information on cohort size, years of follow-up and availability of biomaterial. Endpoint
cardiovascular death includes fatal cardiovascular events such as cerebrovascular diseases; Endpoint cardiovascular events is a combined
endpoint of cardiovascular death and non-fatal myocardial infarction * Median follow-up time. KAROLA, Langzeiterfolge der Kardiologischen
Anschlussheilbehandlung; APACE, Advantageous Predictors of Acute Coronary Syndromes Evaluation Study; stenoCardia, Study for evaluation
of newly onset chest pain and rapid diagnosis of myocardial necrosis
a Data not been harmonized to BiomarCaRE database yet
Table 4 Overall characteristics of the BiomarCaRE disease cohorts
Characteristics
Number of cohorts 4
Number of individuals 8,746
Years of baseline examinations 1996–2012
Men (%) 73
Mean age (SD) at baseline (years) 61.5 (12.4)
Smoker (%) 23
Type 2 diabetes (%) 19
Hypertension (%) 69
The numbers represent individuals at baseline, excluding repeated
measurements. Disease cohort Rome ACB not included as data not
been harmonized to BiomarCaRE database yet
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123based protein biomarker panel will be validated in the
disease cohorts to conﬁrm their value as markers in the
prediction of secondary manifestations of CVD [16]. For
this purpose, development of a 4-plex assay based on a
Luminex platform is ongoing An Enzyme-Linked Immu-
nosorbent Assay (ELISA) is being developed within Bio-
marCaRE to assess cardiovascular risk, speciﬁcally in
women. To investigate circulating miRNAs, a highly ver-
satile multiplex detection platform to support the multiplex
measurement of circulating miRNAs is being developed.
Candidate genes from transcriptomics datasets of
BiomarCaRE partners [38] that may be related to cardio-
vascular events or phenotypes have been selected as bio-
marker targets, and ELISAs for higher throughput
measurements are being developed. The AbsoluteIDQ
p180 kit (www.biocartes.com), which identiﬁes and quan-
tiﬁes 185 metabolites by mass spectrometry, will be used to
proﬁle the metabolome. The metabolome proﬁle and the
transcriptomics-based biomarkers including miRNA will
be assessed within BiomarCaRE in the case cohort setting
(n = 20,000). Figure 3 provides an overview of estab-
lished and emerging biomarkers measured in BiomarCaRE.
Table 5 Clinical trials of
BiomarCaRE
Clinical trials of the project are
listed including information on
trial setting, size, intervention,
duration and primary endpoint
of trial. LIPID, The Long-Term
Intervention with Pravastatin in
Ischaemic Disease Study;
JUPITER, The Justiﬁcation for
the Use of Statins in Primary
Prevention: An Intervention
Trial Evaluating Rosuvastatin
Trial; WHS, The Women’s
Health Study; IBIS-2, Integrated
Biomarker and Imaging Study-
2; hsCRP, high-sensitivity
measured C-reactive protein
Study Setting Size Intervention Median follow
up time (years)
Primary endpoint
LIPID Secondary
prevention
9,014 Pravastatin
(40 mg)
6.1 CHD Death
Non-fatal MI
JUPITER Primary
prevention
17,802 Rosuvastatin
(20 mg)
1.9 MI
Stroke
Cardiovascular death
Hospitalization for
UAP
WHS Primary
prevention
(women only)
39,876 Aspirin (100 mg)
every other day
10.1 Non-fatal MI
Non-fatal stroke
Cardiovascular death
IBIS-2 Secondary
prevention
330 Darapladib
(160 mg)
1 Coronary atheroma
Progression by IVUS
Plaque deformability
by Palpography
hsCRP
Table 6 Number of cases and non-cases in the individual case cohort sets of the cohorts selected for the BiomarCaRE case-cohort study
Study Country Number of incident cases Number of
non-cases
Coronary heart
disease
Stroke Heart
failure
Atrial
ﬁbrillation
Type 2 diabetes
Glostrup Denmark 821 744 608 603 526 2,209
ATBC Placebo Finland 1,414 822 – – – 2,068
FINRISK 97 Finland 354 260 442 307 525 1,384
PRIME France France 286 90 – – – 414
KORA S3/S4 Germany 252 224 – – 390 910
Brianza Italy 218 119 – – – 369
PRIME Belfast United Kingdom 185 53 – – – 282
SHHEC Scotland 940 411 489 475 477 2,055
Total 4,470 2,723 1,539 1,385 1,918 9,691
Numbers are given as status in June 2014. ATBC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; FINRISK, FINRISK Study,
Glostrup, Glostrup Study; SHHEC, Scottish Heart and Health Extended Cohorts; PRIME, Prospective Epidemiological Study of Myocardial
Infarction Study; KORA, Kooperative Gesundheitsforschung in der Region Augsburg; Brianza, The Brianza Study
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123In addition to the emerging, omics-based biomarkers,
novel biomarkers from the literature, such as biomarkers
for heart failure (e.g. soluble isoforms of the IL-1 receptor
family member (sST2) and Galectin-3) are being selected.
An overview of all established and emerging, literature-
based biomarkers to be measured in BiomarCaRE is given
in the Supplementary Material.
Measurement of biomarkers
In Module 2 of the project (Fig. 2), a two-phase approach
for the biomarker measurement is used: in phase 1,
established and novel biomarkers are determined in a set of
population cohorts from different European regions,
including 90,000 subjects with 6,000 incident acute coro-
nary events, 3,800 incident strokes, 3,500 incident cases of
heart failure, 2,600 cases with incident atrial ﬁbrillation
and 2,800 incident type 2 diabetes diagnoses during follow-
up (Table 1). In addition, markers which are considered as
most innovative but ‘‘high risk’’ markers, such as metab-
olites, miRNA and other novel markers derived from omics
approaches will be measured in a case-cohort set of up to
20,000 population-based subjects including 4,500 incident
acute coronary events. This case-cohort design reduces the
number of biomarker measurements without substantially
reducing statistical power [19]. The case-cohort study
involves a random subsample of the selected population
cohorts and in addition all incident cases of these cohorts
(Table 6). Independent of the population-based cohorts, the
selected biomarkers are also measured in the four diseased
cohorts (n = 8,746, Table 3).
In phase 2, the most promising biomarkers from phase 1
are further determined in 130,000 subjects from European
population cohorts (Table 1). Biomarkers measured within
the BiomarCaRE project are depicted in Fig. 3.
Statistical concepts
BiomarCaRE comprises two closely interacting data cen-
tres: one centre that is responsible for the analyses of all
population-derived biomarkers which is based at the
National Institute for Health and Welfare (THL) in Hel-
sinki; Finland. This data centre has a long-standing and
unparalleled experience of epidemiological data harmoni-
zation and central data management and analyses of the
MORGAM Project [9] and its predecessor, the WHO
MONICA Project (Tunstall-Pedoe and Project [32]. The
second data centre is based at the University at Lu ¨beck,
Germany and is responsible for the analyses of biomarkers
derived from the diseased cohorts. Data obtained in clinical
trial repositories will be analysed directly at the respective
partner site. Figure 4 illustrates and summarizes analyses
performed in phases 1 and 2.
As biomarkers may have different effects in healthy and
diseased subjects, the population-based and diseased
cohorts will be analysed separately. The statistical analysis
for both types of cohorts will begin with univariate testing
of each biomarker with adjustment for classical cardio-
vascular risk factors. Signiﬁcant biomarkers are selected
for subsequent analysis in phase 2 cohorts for validation.
The risk models are developed using Cox regression
analysis, taking the case-cohort sampling into account [19]
for some biomarkers. The modelling steps include initial
checking of model assumptions and the stability and par-
simony of biomarker selection. As a complementary
approach for biomarker selection, we will apply random
survival forests [13, 15] which is a machine learning
technique to determine important variables for the predic-
tion of individual survival times. Performance of the risk
estimation models will be cross-validated using calibration,
discrimination indices and graphs and net reclassiﬁcation
improvement. The developed predictive models are com-
pared with established risk score models, such as the
SCORE [6].
The impact of the biomarkers and the predictive models
developed in phase 1 is externally validated using the
prospective population-based cohorts and biomarker data
from phase 2. These analyses will result in the construction
of a risk model including classical risk factors and a
combination of the validated biomarkers (BiomarCaRE
Panel). As a secondary subsidiary aspect, the cross-
Fig. 3 Emerging and established biomarkers measured in phase 1 of
the population-based cohorts (including a case-cohort set) and the
disease cohorts within BiomarCaRE. NTproBNP, N-terminal pro
B-type natriuretic peptide, MR-proANP mid-regional pro atrial
natriuretic papetide; MR-proADM, mid-regional pro adrenomedullin;
hsTnI, high-sensitivity assayed Troponin I; ApoA, apolipoprotein A1;
ApoB100, apolipoprotein B100; Lp(a) Lipoprotein a; CRP, C-reactive
protein
The BiomarCaRE study 785
123sectional association between biomarkers and cardiac
imaging data and between biomarkers and health behaviour
data will be assessed in individual studies where data are
available. Furthermore, joint modelling of repeated mea-
surements of the biomarkers and survival data will be
performed for selected cohorts.
To analyze the effects of various pharmacological
interventions on the BiomarCaRE panel of selected bio-
markers stepwise statistical strategies will be applied in the
clinical trials.
In a ﬁrst step, the predictive value of the BiomarCaRE
panel will be assessed in samples from the clinical trials,
adjusted for medication and stratiﬁed by intervention
group. In a second step, the change in biomarker levels
from baseline to (on average) 1 year on treatment will be
assessed. Finally, the treatment effect will be analyzed
according to biomarker levels at baseline (high vs. low).
Proposed imputation strategy for the BiomarCaRE project
Clinical and biomarker variables are often incomplete due
to e.g. sample unavailability or assay failure. Data analysis
using only complete sets for multiple variables would lead
to loss of available information, thus to reduced statistical
power. Furthermore, the results of such analysis can be
biased. One approach to make the best use of available data
is to predict the missing information from the observed
data. This process minimizes potential bias, and is termed
multiple imputation [8] and will be used in BiomarCaRE
analysis when appropriate. A common strategy in clinical
epidemiology is to exclude variables with more than 20 %
missing data because of the high potential for a severe bias.
If less than 5 % of the data are missing, substantial bias is
unlikely [2]. If 20 % of the biomarker measurements are
missing, the biomarker may be excluded from a multi-
marker analysis, depending on what is known about the
reason for the missing data. Decisions will be made on a
case by case basis.
Economic assessment of single and combined
biomarker application
In the third module of the project (Fig. 2), the focus will be
on the clinical utilisation and cost-effectiveness of the
selected biomarkers, and their single and joint application.
Selected biomarkers from phase 2 will be measured in
samples of clinical trials to test their interaction with risk
lowering therapy (Table 5) and a decision-analytic model
will be developed to estimate long-term effectiveness and
cost-effectiveness of a primary or secondary preventive
strategy based on additional risk assessment using these
biomarkers.
Decision-analytic modelling allows for the combination
of empirical evidence on improvements in risk prediction
and published evidence on short- and long-term effects of
health are interventions to estimate the health effects on
patient-relevant endpoints such as life expectancy or
quality-adjusted life expectancy. Total costs of a strategy
will then be estimated by combining cost savings through
prevention of advanced disease and costs for the biomarker
Fig. 4 Overview of data
analyses performed in phases 1
and 2 of BiomarCaRE
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123panel tests, diagnostic tests and work-up, drug treatment
and monitoring of patients. A decision-analytic state-tran-
sition (Markov) model will be used, as this model type suits
decision problems that can be described in speciﬁc health
states and transition probabilities [5]. The analysis will be
performed as a cohort simulation or as a microsimulation
depending on the number of covariates to be tracked in the
simulation [30], and deterministic and probabilistic sensi-
tivity analyses will be performed. The long-term effec-
tiveness of the biomarker-guided strategies will be
expressed in life years and quality-adjusted life years
(QALY). Cost-effectiveness will be expressed as incre-
mental cost-effectiveness ratios, that is, the additional costs
divided by gains in effectiveness [29]. In particular, we will
systematically vary biomarkers and cut-offs in our model
to identify candidate strategies for effective and cost-
effective biomarker testing that can be investigated in
future clinical trials.
Discussion
The BiomarCaRE project aims to determine the additional
value of multiple (new) biomarkers to improve risk esti-
mation of CVD related events in Europe. The project is
unique in terms of its dimension, targeting of novel bio-
markers based on -omics technology, and the evaluation of
the impact of a multiple biomarker score in large pro-
spective population cohorts across different European
regions. The project integrates modern, mainly SME driven
molecular technologies with epidemiological approaches
supplemented by economical assessment. Evaluation of
biomarkers on a large-scale using high sensitivity tests
improves the precision of the risk estimates. A major
strength of the project is the derivation of novel risk esti-
mation models and assessment in a variety of settings
ranging from general populations to those with disease and
hypothesis-generating clinical trials. The resulting models
may prove most useful in reﬁning risk in subgroups of the
population that could beneﬁt from early treatment.
To date, it is not clear to what extent single or multiple
biomarkers improve CVD prediction and how they provide
additional information for therapy selection and guidance.
Ideally, selection of biomarkers and generation of multi-
marker panels would be based both on biological plausi-
bility (and independent causal effects) and empirical evi-
dence on their inﬂuence on disease risk. However, the
causal relevance of many predictive biomarkers of CVD
has yet to be fully established, but this may not necessarily
be required for risk prediction. Recent research has dem-
onstrated that scores comprising biomarkers that show low
to moderate correlation between each other and represent
different biological pathways could improve discrimination
and calibration [4, 14, 25]. As the number of pathways
known to contribute to cardiovascular risk is expanding,
selection of biomarkers from different pathways is chal-
lenging. The added value contributed by the BiomarCaRE
consortium is the ability to capitalise on proteomics, met-
abolomics, transcriptomics and miRNAomics approaches
which may yield promising candidate markers from novel
pathways which can be compared robustly to other estab-
lished and emerging biomarkers. This is based on newly
developed technologies to apply innovative biomarkers on
a large-scale basis. Furthermore, the project will extend our
knowledge of biomarker-driven prognostication to
encompass the wider cost-effectiveness implications using
a simulation approach.
The ultimate goal of BiomarCaRE, building a robust
European risk score, would greatly facilitate individualized
risk estimation, screening, and diagnosis of CVD. The
novel risk score would carry the potential to change
existing guidelines and could thus have signiﬁcant public
health impact.
Current research further suggests that considerable dif-
ferences exist between women and men with respect to
disease mechanisms and outcomes. However, small num-
ber of women developing manifest disease in population
studies has often made it difﬁcult to assess sex differences.
Furthermore, women are not adequately represented in
clinical trials. Thus, gender-speciﬁc analyses have been
mostly underpowered. Because of the increasing incidence
of CVD in women, there is a need to gain insight into
gender-speciﬁc biomarker properties. Within BiomarCaRE
the large cohort size will allow gender-based subgroup
analyses with sufﬁcient power.
Expected outcome and perspective of personalized
medicine in Europe
The BiomarCaRE project will be in a unique position to
carefully design pragmatic randomized controlled trials to
understand the clinical implications of reclassiﬁcation, in
particular to establish the safety and effectiveness of
deferring treatment for those reclassiﬁed into a lower risk
category based on biomarkers. Further, the study will give
clues to whether any intensiﬁed intervention in those
reclassiﬁed to higher risk categories might ultimately result
in improved clinical outcomes. In this regard, BiomarCaRE
has already initiated the planning of the ‘‘post’’ Biomar-
CaRE phase that will prospectively validate clinical util-
isation in personalised medicine, by proposing the
execution of a biomarker guided clinical trial utilizing the
results of the BiomarCaRE consortium.
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